{
    "nctId": "NCT03980093",
    "briefTitle": "The REACH Study: A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors",
    "officialTitle": "A Novel Values-Based Intervention to Increase Endocrine Therapy Adherence Among Breast Cancer Survivors",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "NA",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "SUPPORTIVE_CARE",
    "enrollmentCount": 88,
    "primaryOutcomeMeasure": "Medication adherence assessed by electronic pillbox (Wisepill box)",
    "eligibilityCriteria": "Inclusion Criteria include:\n\n1. Women in Colorado treated for Stage 0 to III estrogen receptor-positive breast cancer who have completed primary cancer treatment (surgery, chemotherapy, and/or radiation) and within the past 2.5 years, have been prescribed anti-hormonal therapy\n2. Take their anti-hormonal therapy medication at least occasionally and have at least 1 more year left on their prescription\n3. Report at least 1 factor that makes taking their anti-hormonal therapy medication difficult\n4. Have internet access",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}